Technology | January 12, 2012

Hyperthermia System Increases Cervical Cancer Response to Radiation Therapy

 

January 12, 2012 -- The U.S. Food and Drug Administration (FDA) recently cleared a hyperthermia system designed to warm cervical cancer tumors so they respond better to radiation therapy treatments.

The BSD Medical BSD-2000 Hyperthermia System delivers focused therapeutic heating (hyperthermia) with temperatures greater than 104 degrees Fahrenheit, to cancerous tumors by applying radiofrequency (RF) energy. The energy is delivered in the frequency range of 75 to 120 MHz. The BSD-2000 delivers RF energy to a patient using a power source and an array of antennae that surround the patient’s body. The energy can be electronically focused to produce a localized electromagnetic power field. This can be adjusted to target the three-dimensional shape, size and location of the tumor, providing dynamic control of the heat delivered to the tumor region. This method of therapeutic heating utilizes the adjustment of frequency, phase, and amplitude from multiple power sources, along with an applicator selection and patient positioning, to optimize heating of the targeted body tissues.

The system is indicated for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The FDA said it increases the response of tumor cells to radiation therapy.

The FDA said the system should not be used in patients who have:

  • medical devices that are implanted, carried or worn on their bodies
  • severe dysfunction of the heart or lungs
  • electrically conductive, metal, or foreign objects in, on or attached to their body
  • severe high or low blood pressure
  • severe cerebrovascular disease, or
  • when the treating physician cannot place either a temperature sensor into the tumor or into a body cavity.

For a summary of safety and probable benefit (SSPB) and product labeling, visit www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=h090002

 

 

Related Content

Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...